Drug General Information
| Drug Name |
Sorafenib
|
||
| Synonyms |
Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
|
||
| Drug Type |
Small molecular drug
|
||
| Indications |
Hepatocellular carcinoma [ICD-11: 2C12.02]
|
Phase 3
|
|
|
Myelodysplastic syndrome [ICD-11: 2A37]
|
Phase 2
|
||
|
Renal cell carcinoma [ICD-11: 2C90]
|
Approved
|
||
| Company |
Bayer AG; Onyx Pharmaceuticals
|
||
| Summary |
Sorafenib is a kinase inhibitor used to treat unresectable liver carcinoma, advanced renal carcinoma, and differentiated thyroid carcinoma.
|
||
| Target |
Vascular endothelial growth factor receptor 2 (KDR)
Mechanism of Action: Modulator
|
T80975 | |
|
Epidermal growth factor receptor (EGFR)
Mechanism of Action: Inhibitor
|
T59328 | ||
|
Tyrosine-protein kinase Kit (KIT)
Mechanism of Action: Modulator
|
T57700 | ||
|
Platelet-derived growth factor receptor beta (PDGFRB)
Mechanism of Action: Modulator
|
T59102 | ||
Drug Chemical Infomation and External Links
|
Formula |
C21H16ClF3N4O3
|
| Canonical SMILES |
CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
|
|
| InChI |
1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
|
|
| InChIKey |
MLDQJTXFUGDVEO-UHFFFAOYSA-N
|
|
| CAS Number | CAS 284461-73-0 | |
| TTD ID | D0W5HK | |
| DrugBank ID | DB00398 | |
| PubChem Compound ID | 216239 | |
| PubChem Substance ID |
833589
,
833590
,
7886069
,
9372814
,
12015507
,
14720365
,
14834034
,
30419984
,
46505329
,
46516901
,
50069824
,
50070560
,
50071324
,
50100118
,
50112741
,
53787819
,
53799234
,
56312334
,
56312336
,
56312338
,
56312517
,
56312519
,
56312521
,
56394953
,
57399755
,
68529952
,
74382940
,
75518900
,
81092852
,
85174603
,
85285882
,
85845166
,
91148447
,
92718861
,
93581025
,
96025209
,
99443909
,
103420820
,
103904444
,
104178872
,
113461200
,
117695450
,
117871124
,
124767621
,
124893320
,
124893321
,
124893322
,
124893323
,
124893324
,
125346960
|
|
| ChEBI ID | CHEBI:50924 | |
| ADReCS Drug ID | BADD_D02058 |
Drug-Food (Herb) Interactions
- Drug
- Foods
- Herbs
- Positive
- Negative
- Possible
- Harmful
- No Effect
| ID | Name | Dose | Type | Drug Brand Name | Drug Dose | Drug Dosage Form | Experimental Species | Individuals Number | Test Sample | Ingredient | Effect | Relationship Classification | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | Name | Dose | Type | Drug Brand Name | Drug Dose | Drug Dosage Form | Experimental Species | Individuals Number | Test Sample | Ingredient | Effect | Relationship classification |